Real-world data reveals how often breast cancer patients stop or adjust T-DXd therapy
NCT ID NCT06386263
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study looked at 22 adults with advanced HER2-positive or HER2-low breast cancer who were taking the drug trastuzumab deruxtecan (T-DXd). Researchers wanted to see how often patients stopped treatment early or needed dose changes in everyday medical practice. The goal was to better understand how the drug works outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Oakville, Ontario, L6H1A7, Canada
Conditions
Explore the condition pages connected to this study.